Topics

Human medicines European public assessment report (EPAR): Revlimid, lenalidomide, Multiple Myeloma,Lymphoma, Mantle-Cell,Myelodysplastic Syndromes, Date of authorisation: 14/06/2007, Revision: 40, Status: Authorised

10:36 EST 11 Feb 2020 | European Medicines Agency

Human medicines European public assessment report (EPAR): Revlimid, lenalidomide, Multiple Myeloma,Lymphoma, Mantle-Cell,Myelodysplastic Syndromes, Date of authorisation: 14/06/2007, Revision: 40, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Revlimid, lenalidomide, Multiple Myeloma,Lymphoma, Mantle-Cell,Myelodysplastic Syndromes, Date of authorisation: 14/06/2007, Revision: 40, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Revlimid, lenalidomide, Multiple Myeloma,Lymphoma, Mantle-Cell,Myelodysplastic Syndromes, Date of authorisation: 14/06/2007, Revision: 40, Status: Authorised"

Quick Search